Nanoviricides Reports That The Ultra-broad-spectrum Antiviral NV-387, A Phase 2 Stage Drug Candidate, Was Found To Be Effective In Protecting Lungs From Damage In A Lethally Infected Influenza H3N2 Mouse Model
Portfolio Pulse from Benzinga Newsdesk
Nanoviricides announced that its Phase 2 drug candidate, NV-387, demonstrated effectiveness in protecting lungs from damage in a lethally infected influenza H3N2 mouse model.
June 20, 2024 | 10:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nanoviricides' Phase 2 drug candidate NV-387 has shown effectiveness in protecting lungs from damage in a lethally infected influenza H3N2 mouse model, which could boost investor confidence and positively impact the stock price.
The positive results from the Phase 2 drug candidate NV-387 in a critical influenza model can significantly boost investor confidence in Nanoviricides' pipeline, likely leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100